Voss Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Voss Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-650,000	Closed	-$1.41M	–	69
2025 Q3	$1.41M	Sell	650,000 -22,570	-3%	-$53.3K	0.07%	47
2025 Q2	$1.16M	Buy	+672,570	New	+$1.67M	0.08%	48
2020 Q3	–	Sell	-40,000	Closed	-$1.1M	–	55
2020 Q2	$1.1M	Buy	+40,000	New	+$1.32M	0.73%	27

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voss Capital's IOVA Position: Q4 2025 in Review

Voss Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2025, closing a stake of 650,000 shares — an estimated $1.41M sold.

Voss Capital first reported a position in IOVA in Q2 2020 and held it in 3 quarters. The position peaked at $1.41M in Q3 2025. 263 funds tracked by Wall St. Rank hold IOVA as of Q4 2025.

Voss Capital reported no remaining Iovance Biotherapeutics position as of Q4 2025 after selling out during the quarter.
Voss Capital sold 650,000 Iovance Biotherapeutics shares in Q4 2025, an estimated $1.41M.
Voss Capital first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 3 quarters.
Voss Capital's Iovance Biotherapeutics position peaked at $1.41M in Q3 2025.
263 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2025.

Based on Voss Capital's 13F filing for Q4 2025, filed 13 Feb 2026.